ABCB1 Gene Is Associated With Clinical Response to SNRIs in a Local Chinese Han Population

Area of Science:

• Pharmacogenetics
• Neuroscience
• Genetics

Background:

• The ATP-binding cassette subfamily B member 1 (ABCB1) gene has been implicated in major depressive disorder (MDD).
• Previous studies in Chinese Han populations suggest associations between specific ABCB1 single-nucleotide polymorphisms (SNPs) and MDD, though findings vary.
• Understanding the role of ABCB1 in treatment response is crucial for personalized medicine in MDD.

Purpose of the Study:

• To investigate the association between ABCB1 gene polymorphisms and therapeutic responses to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).
• To explore the predictive value of ABCB1 SNPs for treatment outcomes in a Chinese Han population with MDD.

Main Methods:

• A cohort of 292 MDD patients was recruited from a local Chinese Han population.
• Patients were treated with either SSRIs or SNRIs and assessed weekly for six weeks using the 17-item Hamilton Rating Scale for Depression (HAM-D17).
• Genotyping of six ABCB1 SNPs was performed, and their distribution was compared between treatment responders and non-responders.

Main Results:

• No significant differences in genotype or allele distribution of the six studied ABCB1 SNPs were found between responders and non-responders in the SSRI therapy group.
• In the SNRI therapy group, the ABCB1 rs2032583 polymorphism was significantly associated with therapeutic response.
• Logistic regression analysis indicated that the C allele of ABCB1 rs2032583 was negatively correlated with treatment response to SNRIs, suggesting the TT genotype may predict better outcomes.

Conclusions:

• ABCB1 gene polymorphisms do not appear to be associated with therapeutic responses to SSRIs in this MDD cohort.
• The rs2032583 polymorphism in the ABCB1 gene may serve as a predictive factor for improved treatment response to SNRIs among Chinese patients with MDD.
• Further validation in larger, diverse patient cohorts is recommended to confirm these findings.